West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%

WEST PHARMACEUTICAL SERVICES INC

2022-Q3 EPS reported $6.36 revenue$2,178,200,000

Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.
Reported EPS $1.59 (-31.2%); adjusted EPS $2.03 (-1.5%); Biologics and Generics mid-single digit organic growth.
FY2022 guidance cut: net sales $2.830-2.840B (prior $2.950-2.975B), adjusted EPS $8.15-8.20 (prior $9.00-9.15).
Dividend raised 5.6% to $0.19/share, payable Nov 16 to holders of record Nov 9; 30th consecutive annual increase.
Management cited delays in expansion projects and customer mix-shift; expects resolution early 2023; capex guidance lowered to $300-320M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.

Period: Third-Quarter 2022
EPS: 2.03
Result: reported results

Exact text from the filing

(610) 594-3054 Quintin.Lai@westpharma.com Michele.Polinsky@westpharma.com --- EX-99.2 (EX-99.2) --- finalwestq3oct2022 1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M | 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.

Period: Third-Quarter 2022
EPS: 2.03
Result: reported results

Exact text from the filing

• Adjusted-diluted EPS of $2.03 declined 1.5%. • Company is updating full-year 2022 net sales guidance to a new range of $2.830 billion to $2.840 billion, compared to a prior range of $2.950 billion to $2.975 billion.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-22-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.